Abstract
First synthesized in 1854, it took more than 30 years for the toxic properties of the alkylating agents to be acknowledged in 1887. As unfortunate as it may be, their first use as “nitrogen mustard” occurred in World War I when they were developed as chemical warfare irritants to the conjunctiva, skin, and lungs becoming one of the famous “incapacitating” weapons ever to be used in chemical warfare. The wounded soldiers demonstrated that nitrogen mustard not only caused serious burning of external skin and mucus membranes but also resulted in deadly bone marrow aplasia.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Akpek EK, Jabs DA, Tessler HH et al (2002) Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 109:1506–1513
Baker KB, Spurrier NJ, Watkins AS et al (2006) Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol 90:1481–1585
Durrani K, Papaliodis GN, Foster CS (2004) Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 111:960–965
Kazokoglu H, Saatçi O, Cuhadaroglu H, Eldem B (1991) Long-term effects of cyclophosphamide and colchicine treatment in Behçet’s disease. Ann Ophthalmol 23:148–151
Khan IJ, Barry RJ, Amissah-Arthur KN, Carruthers D, Elamanchi SR, Situnayake D, Murray PI, Denniston AK, Rauz S (2013) Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease. Br J Ophthalmol 97(9):1118–1122
Miserocchi E, Baltatzis S, Roque MR et al (2002) The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 109:111–118
Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel, vasculitis. Ann Rheum Dis 68:310–317
Ozyazgan Y, Yurdakul S, Yazici H et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243
Pujari SS, Kempen JH, Newcomb CW, Gangaputra S et al (2010) Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117(2):356–365
Rosenbaum JT (1994) Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 21:123–125
Suelves AM, Arcinue CA, González-Martín JM, Kruh JN, Foster CS (2013) Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. Ophthalmology 120(6):1201–1209
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Neumann, R. (2016). Cyclophosphamide. In: Zierhut, M., Pavesio, C., Ohno, S., Orefice, F., Rao, N. (eds) Intraocular Inflammation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-75387-2_24
Download citation
DOI: https://doi.org/10.1007/978-3-540-75387-2_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-75385-8
Online ISBN: 978-3-540-75387-2
eBook Packages: MedicineMedicine (R0)